Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncology Start-up Cyterix Pharmaceuticals Launches With $9.2MM From VCs

This article was originally published in The Pink Sheet Daily

Executive Summary

Two venture firms bet on the Scottish university spin-out, now based California, as it develops pro-drugs activated by a specific enzyme family.

You may also be interested in...

Exelixis Slashes Staff Again, Focuses All Internal Development on XL184

As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.

Ablexis' Pharmaceutical Consortium

Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.

Making The Case For Antibody-Drug Conjugates

After 30 years and one market failure, antibody-drug conjugate developers have produced two strong clinical candidates, with a lot more coming in the pipeline. Can two successes turn into the next great therapeutic platform?





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts